SLAMF1/CD150 expression and topology in prostate and breast cancer cell lines.

Abstract

SLAMF1/CD150receptor is aberrantly expressed in malignant hematopoietic cells compared to ubiquitous expression in their normal analogues. However, the data about CD150expression and function outside the hematopoietic system arelimited. The aim of this pilot study was to examine the profile of mRNA expression of CD150isoforms and the protein topology in highly and low malignant breast (BC) and prostate cancer (PC) cell lines. The study was performed on BCT47D, MDA-MB-231, ВСС/Р and BC/ML cell lines and PC LNCap, Du-145and PC-3cell lines. The quantitative polymerase chain reaction was applied for study of CD150isoforms mRNA expression and flow cytometry was used for determination of protein localization. Analyzed BC cell lines did not express CD150on the cell surface membrane (csCD150-), but more than 45% of cells were positive for CD150cytoplasmic reaction (cyCD150+). The cyCD150expression level in T47D cells of luminal BC subtype was higher than in basal BC cell lines MDA-MB-231, ВСС/Р and BC/ML. The PC cell lines expressed CD150both on the cell surface and in cytoplasm. The highest number of csCD150+ and cyCD150+ cells was revealed in less aggressive androgen responsive, non-metastatic LNCap cell line. All studied BC and PC cell lines expressed mRNA of canonical transmembrane mCD150and novel nCD150isoforms but with different pattern of prevalence. Soluble CD150isoform was revealed at the low level only in BCC/P BC cell line and LNCap, PC-3PC cell lines. We have shown that BC and PC cell lines differentially expressed multifunctional receptor CD150at the mRNA and protein levels that may indicate its association with the degree of their malignancy.